En Bloc Multivisceral and Kidney Transplantation in an HIV Patient: First Case Report. 2016

C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
Department of Infectious Disease, Cleveland Clinic, Cleveland, OH.

The continual improvement in outcome with highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection and visceral transplantation for gut failure stimulated our interest in lifting HIV infection as a contraindication for intestinal and multivisceral transplantation. This report is the first to describe visceral transplantation in a patient with HIV infection. A HAART regimen was introduced in the setting of short-gut syndrome with successful suppression of HIV viral load. The indication for en bloc multivisceral and kidney transplantation was end-stage liver failure with portomesenteric venous thrombosis and chronic renal insufficiency. The underlying hepatic pathology was alcoholic and home parenteral nutrition-associated cirrhosis. Surgery was complicated due to technical difficulties with excessive blood loss and long operative time. The complex posttransplant course included multiple exploratory laparotomies due to serious intra-abdominal and systemic infections. Heavy immunosuppression was required to treat recurrent episodes of severe allograft rejection. Posttransplant oral HAART successfully sustained undetectable viral load. Unfortunately, the patient succumbed to sepsis 3 months posttransplant. With new insights into the biology of gut immunity, mechanisms of allograft tolerance, and HIV-associated immune dysregulation, successful outcome is anticipated, particularly in patients who are in need of isolated intestinal and less-organ-contained visceral allografts.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated

Related Publications

C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
March 1988, The Journal of urology,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
July 2012, Indian journal of urology : IJU : journal of the Urological Society of India,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
April 2012, Indian journal of urology : IJU : journal of the Urological Society of India,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
September 2018, Transplantation direct,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
June 2011, Transplantation proceedings,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
February 2020, Pediatric transplantation,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
January 2000, International surgery,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
November 2005, The Journal of urology,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
March 2005, Transplantation,
C E Koval, and A Khanna, and A Pallotta, and M Spinner, and A J Taege, and B Eghtesad, and M Fujiki, and K Hashimoto, and B Rodriguez, and G Morse, and A Bennett, and K Abu-Elmagd
January 2012, International journal of organ transplantation medicine,
Copied contents to your clipboard!